DNTH today
$91.81-$0.67 (-0.72%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minBullish
5 minBullish
Daily trend turns up above $111.11
Key levels
Resistance$102.38
Resistance$93.85
Support$87.40
Support$80.74
Latest news & SEC filings
SEC FilingDianthus Therapeutics, Inc. filed an insider trading report (Form 4)
EarningsDianthus Therapeutics Posts Q3 2026 Financials
EarningsDianthus Therapeutics to report Q3 2026 financial results
All DNTH news →About Dianthus Therapeutics
Dianthus Therapeutics is a biotechnology firm in the clinical testing phase, working on treatments for serious conditions in which the body's immune system attacks itself. Its main candidate, claseprubart, is an antibody given as an under-the-skin shot that blocks only one specific complement protein, and it is under study for three nerve and muscle disorders: generalized myasthenia gravis, CIDP, and multifocal motor neuropathy. A second candidate, DNTH212, is a dual-targeting fusion protein aimed at autoimmune indications. The company is based in the United States and in-licenses DNTH212 from a Chinese partner.
Based on the company's 10-K filed Mar 9, 2026.
Nasdaq · Healthcare
Dianthus Therapeutics, Inc. /DE/ (DNTH)
What Is the Price Target for DNTH?
SEPT Low Target
$98.00
SEPT Mid Target
$134.00
SEPT High Target
$158.00
Analyst Consensus
$134.00
Is DNTH a Buy or Sell Right Now?
Thesis
- •Revenue growing -67.3% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DNTH.
Start Free Trial →Is DNTH Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$113.94
25
Moat Score
NONE
1/9
Piotroski Score
49.7
Altman Z-Score
What Is Smart Money Doing with DNTH?
Insider Signal
SELLING
0 buys / 12 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Savitz Ryan | officer | Buy | 1,339 | $29K | Nov 12, 2026 |
| Savitz Ryan | officer | Buy | 16,385 | $362K | Nov 12, 2026 |
| Savitz Ryan | officer | Sale | 17,724 | $1.6M | Nov 12, 2026 |
| Savitz Ryan | officer | Buy | 1,744 | $38K | Nov 11, 2026 |
| Savitz Ryan | officer | Buy | 1,300 | $29K | Nov 11, 2026 |
| Savitz Ryan | officer | Sale | 3,044 | $274K | Nov 11, 2026 |
| Savitz Ryan | officer | Buy | 1,301 | $28K | Nov 10, 2026 |
| Savitz Ryan | officer | Buy | 1,260 | $28K | Nov 10, 2026 |
| Savitz Ryan | officer | Sale | 2,561 | $231K | Nov 10, 2026 |
| Savitz Ryan | officer | Buy | 29,276 | $523K | Nov 9, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →DNTH Growth Story
Revenue YoY
-67.3%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-64.71%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for DNTH
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for DNTH, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:53:08 | $89.39 | 1,100 | $$98K | SELL |
| 21:00:53 | $92.48 | 2,562 | $$237K | SELL |
| 21:00:53 | $92.48 | 1,688 | $$156K | SELL |
| 21:00:53 | $92.48 | 2,175 | $$201K | SELL |
| 21:00:53 | $92.48 | 1,200 | $$111K | SELL |
5 dark pool trades shown · $$803K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Dianthus Therapeutics, Inc. /DE/ (DNTH) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →DNTH — frequently asked questions
What is DNTH stock price today?
Dianthus Therapeutics, Inc. /DE/ (DNTH) is at $91.81, down 0.72% (-$0.67) at the Nov 13, 2026 close.
Why is DNTH stock moving today?
Latest DNTH news — Nov 12, 2026: Dianthus Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 4, 2026: Dianthus Therapeutics Posts Q3 2026 Financials
What is the DNTH price target?
The average analyst price target for DNTH is $134.00, ranging from $98 to $158, based on 9 analysts. Latest: Roth Capital initiates on Oct 27, 2026.
What do analysts rate DNTH?
Analyst ratings for DNTH: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
Did DNTH beat earnings?
DNTH last reported on Aug 4, 2026: EPS -$0.90 vs -$0.85 expected — a miss of 6.3%.
Does DNTH pay a dividend?
DNTH does not currently pay a dividend.
What are DNTH support and resistance levels?
Support: $87.40, $80.74, $75.40. Resistance: $93.85, $102.38, $111.11.
What are insiders doing with DNTH?
Insider activity: SELLING, 0 buys and 12 sells in the last 90 days.
What is the latest news on DNTH?
Nov 12, 2026: Dianthus Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 4, 2026: Dianthus Therapeutics Posts Q3 2026 Financials · Nov 4, 2026: Dianthus Therapeutics to report Q3 2026 financial results